Skip to main content
. 2015 Mar 15;8(3):4320–4327.

Table 3.

Analysis of liver therapy efficacy

Result Experimental group (%) Control group (%) Total Statistics P
No liver function abnormalities or symptoms 173 (62.45) 193 (66.32) 366
Transient liver function abnormalities or symptoms 95 (34.30) 80 (27.49) 175 -0.649 0.516
Liver injury and symptoms with interrupted anti-TB treatment 9 (3.25) 18 (6.19) 27
Total 277 291 568

Note: The groups were compared using the Wilcoxon test.